STOCKHOLM, July 1, 2022 /PRNewswire/ -- Hemcheck Sweden AB has signed a distributor agreement with SDO Medical regarding the Spanish market. The agreement entails an initial evaluation period of 6 months and a requirement for a first order.
- SDO Medical has shown strong interest and has many customer contacts in the Spanish market. They will focus on customers in both diagnostic and non-diagnostic use. We look forward to starting the collaboration with them and we believe that they can be a good partner for us in Spain, says Joen Averstad, CEO of Hemcheck.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck's goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.
This information was brought to you by Cision http://news.cision.com
The following files are available for download: